Effects of metformin on BRIN-BD11 beta-cell insulin secretory desensitization induced by prolonged exposure to sulphonylureas

Diabetes, Obesity and Metabolism

Volumn 12, Issue 12, 2010, Pages 1066-1071

  Irwin, Nigel ^a   McKinney, J M ^a   Bailey, C J ^b   Flatt, P R ^a   McClenaghan, N H ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

Clonal pancreatic cell; Desensitization; Insulin release; Metformin; Sulphonylurea

Indexed keywords

ALANINE; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; METFORMIN; TOLBUTAMIDE;

ARTICLE; CELL GROWTH; CELL VIABILITY; CONCENTRATION RESPONSE; DESENSITIZATION; DRUG EFFECT; DRUG EXPOSURE; INSULIN RELEASE; PANCREAS ISLET BETA CELL;

EID: 77958553980     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01294.x     Document Type: Article

References (31)

1. + channels and insulin secretion: their role in health and disease. Diabetologia 1999; 42: 903-919.
2. Flatt PR, Shibier O, Szecowka J, Berggren PO. New perspectives on the actions of sulphonylureas and hyperglycaemic sulphonamides on the pancreatic beta-cell. Diabete Metab 1994; 20: 157-162.
3. Eliasson L, Renström E, Ammälä C et al. PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cells. Science 1996; 271: 813-815.
4. Tian YA, Johnson G, Ashcroft SJ. Sulfonylureas enhance exocytosis from pancreatic beta-cells by a mechanism that does not involve direct activation of protein kinase C. Diabetes 1998; 47: 1722-1726.
5. Kamp F, Kizilbash N, Corkey BE, Berggren PO, Hamilton JA. Sulfonylureas rapidly cross phospholipid bilayer membranes by a free-diffusion mechanism. Diabetes 2003; 52: 2526-2531.
6. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
7. Ball AJ, Flatt PR, McClenaghan NH. Desensitization of sulphonylurea- and nutrient-induced insulin secretion following prolonged treatment with glibenclamide. Eur J Pharmacol 2000; 408: 327-333.
8. Brennan L, Hewage C, Malthouse JP, McClenaghan NH, Flatt PR, Newsholme P. Investigation of the effects of sulfonylurea exposure on pancreatic beta cell metabolism. FEBS J 2006; 273: 5160-5168.
9. McClenaghan NH, Ball AJ, Flatt PR. Specific desensitization of sulfonylurea- but not imidazoline-induced insulin release after prolonged tolbutamide exposure. Biochem Pharmacol 2001; 61: 527-536.
10. Bailey CJ. Metformin: a multitasking medication. Diabetes Vasc Dis Res 2008; 5: 15.
11. Bailey CJ, Turner RC. Metformin. N Eng J Med 1996; 334: 574-579.
12. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
13. Stargardt T, Yin DD, Alexander CM. Treatment choice and effectiveness of adding sulphonylurea or glitazones to metformin for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab 2009; 11: 491-497.
14. Leclerc I, Rutter GA. AMP-activated protein kinase: a new beta-cell glucose sensor?: regulation by amino acids and calcium ions. Diabetes 2004; 53: S67-S74.
15. Sun G, Tarasov AI, McGinty J et al. Ablation of AMP-activated protein kinase alpha1 and alpha2 from mouse pancreatic beta cells and RIP2.Cre neurons suppresses insulin release in vivo. Diabetologia 2010; 53: 924-936.
16. Khan SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
17. Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 2007; 27: 1102-1110.
18. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295.
19. McClenaghan NH, Barnett CR, Ah-Sing E et al. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 1996; 45: 1132-1140.
20. 2+ signalling in single clonal insulin-secreting cells: evidence for a mixed model of cellular activation. Int J Biochem Cell Biol 2000; 32: 557-569.
21. Ball AJ, Flatt PR, McClenaghan NH. Acute and long-term effects of nateglinide on insulin secretory pathways. Br J Pharmacol 2004; 142: 367-373.
22. McClenaghan NH, Flatt PR, Ball AJ. Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide. J Endocrinol 2006; 190: 889-896.
23. Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in heterozygous (ob/+) mice. Diabetelogia 1981; 20: 573-577.
24. Richards SK, Parton LE, Leclerc I, Rutter GA, Smith RM. Over-expression of AMP-activated protein kinase impairs pancreatic {beta}-cell function in vivo. J Endocrinol 2005; 187: 225-235.
25. Wang CZ, Wang Y, Di A et al. 5-amino-imidazole carboxamide riboside acutely potentiates glucose-stimulated insulin secretion from mouse pancreatic islets by KATP channel-dependent and -independent pathways. Biochem Biophys Res Commun 2005; 330: 1073-1079.
26. Salt IP, Johnson G, Ashcroft SJ, Hardie DG. AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem J 1998; 335: 533-539.
27. Zhang S, Kim KH. Glucose activation of acetyl-CoA carboxylase in association with insulin secretion in a pancreatic beta-cell line. J Endocrinol 1995; 147: 33-41.
28. Riboulet-Chavey A, Diraison F, Siew LK, Wong FS, Rutter GA. Inhibition of AMP-activated protein kinase protects pancreatic beta-cells from cytokine-mediated apoptosis and CD8+ T-cell-induced cytotoxicity. Diabetes 2008; 57: 415-423.
29. Takahashi A, Nagashima K, Hamasaki A et al. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. Diabetes Res Clin Pract 2007; 77: 343-350.
30. Nyblom HK, Sargsyan E, Bergsten P. AMP-activated protein kinase agonist dose dependently improves function and reduces apoptosis in glucotoxic beta-cells without changing triglyceride levels. J Mol Endocrinol 2008; 41: 187-194.
31. McKiney JM, Irwin N, Flatt PR, Bailey CJ, McClenaghan NH. Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal β-cells. Biol Chem 2010 [Epub ahead of print].